Background/Aim: To predict the efficacy of platinum-containing chemotherapy, ERCC1 expression levels were investigated. Studies have shown changes in the performance of anti-ERCC1 antibodies; therefore, predicting chemotherapy efficacy by immunohistochemical assessment of ERCC1 is controversial. Patients and Methods: Twenty-eight patients who received platinum-containing chemotherapy and underwent computed tomography evaluation 6-9 weeks after therapy initiation were retrospectively identified. The tumor samples were evaluated in 2012 and 2018 using the latest anti-ERCC1 antibodies available at those times. Results: In 2012, the ERCC1 H-score was significantly higher in patients with disease progression than in patients without disease progression (p=0.019). Although the same trend was shown in 2018, there were some inconsistent results between the 2012 and 2018 samples. Conclusion: Patients with tumors showing low ERCC1 expression had a better disease control rate on platinumcontaining chemotherapy. However, since the performance of the antibody changed over time, standardized technology to evaluate ERCC1 expression is needed.
CITATION STYLE
Okimoto, T., Tsubata, Y., Tanino, R., Nakao, M., Hotta, T., Hamaguchi, M., … Isobe, T. (2021). ERCC1 Is a predictive biomarker for non-small cell lung cancer but is antibody-dependent. Anticancer Research, 41(5), 2653–2660. https://doi.org/10.21873/ANTICANRES.15046
Mendeley helps you to discover research relevant for your work.